A Medscape commentary explores why endocrinologist Caroline Messer, MD, decided to begin taking a GLP-1 medication at age 48. According to the piece, her choice was shaped in part by her mother’s history of Alzheimer’s disease and her own thinking about long-term brain health.
Messer says the decision was not driven by weight loss. In the article, she notes that she regularly talks with patients about GLP-1 drugs in her clinical practice, but has now become a patient herself. Her perspective highlights how these medications are being considered not only for metabolic health, but also in broader discussions about future disease risk.
The commentary makes clear that there is no definitive evidence that GLP-1 medications can prevent Alzheimer’s disease. Even so, the article describes why a physician familiar with the science and the uncertainties concluded that starting treatment made sense for her personally.
The piece reflects a growing public and medical interest in whether GLP-1 drugs could have benefits beyond blood sugar control and weight management. At the same time, it underscores the gap between emerging interest and proven outcomes, especially when it comes to Alzheimer’s prevention.
